Ekterly Momentum: A Tactical Long on KalVista (KALV) Backed by Early Commercial Traction
KalVista's oral HAE drug Ekterly produced $1.4M in Q1 FY2026 sales and the company has transitioned to commercial operations. The shares trade around $20 with a market cap near $1.03B, but technicals and mounting short interest set the stage for a mid-term swing. This trade idea targets continued uptake over the next ~45 trading days while protecti…